La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Phio Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Phio Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 183.3% et de 213.8% par an respectivement, tandis que le BPA devrait croître de croître de 162% par an.

Informations clés

183.3%

Taux de croissance des bénéfices

162.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.0%
Taux de croissance des recettes	213.8%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	14 May 2024

Mises à jour récentes de la croissance future

Recent updates

Phio Pharmaceuticals appoints interim executive chairman

Sep 29

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Aug 11

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Apr 11

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Nov 09

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:PHIO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	75	48	N/A	N/A	1
12/31/2024	N/A	-10	N/A	N/A	1
6/30/2024	N/A	-9	-9	-9	N/A
3/31/2024	N/A	-9	-10	-10	N/A
12/31/2023	N/A	-11	-11	-11	N/A
9/30/2023	N/A	-12	-11	-11	N/A
6/30/2023	N/A	-12	-12	-12	N/A
3/31/2023	N/A	-12	-11	-11	N/A
12/31/2022	N/A	-11	-12	-12	N/A
9/30/2022	N/A	-12	-12	-12	N/A
6/30/2022	N/A	-12	-11	-11	N/A
3/31/2022	N/A	-13	-12	-12	N/A
12/31/2021	N/A	-13	-12	-12	N/A
9/30/2021	N/A	-12	-12	-12	N/A
6/30/2021	N/A	-11	-11	-11	N/A
3/31/2021	N/A	-10	-10	-10	N/A
12/31/2020	N/A	-9	-9	-9	N/A
9/30/2020	N/A	-9	-9	-9	N/A
6/30/2020	N/A	-9	-9	-9	N/A
3/31/2020	N/A	-9	-9	-9	N/A
12/31/2019	0	-9	-9	-9	N/A
9/30/2019	0	-8	-8	-8	N/A
6/30/2019	0	-7	-8	-8	N/A
3/31/2019	0	-7	-8	-8	N/A
12/31/2018	0	-7	-8	-8	N/A
9/30/2018	0	-8	-8	-8	N/A
6/30/2018	0	-9	-8	-8	N/A
3/31/2018	0	-9	N/A	-9	N/A
12/31/2017	0	-12	N/A	-10	N/A
9/30/2017	N/A	-15	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	0	-14	N/A	-8	N/A
12/31/2016	0	-11	N/A	-8	N/A
9/30/2016	0	-9	N/A	-8	N/A
6/30/2016	0	-10	N/A	-8	N/A
3/31/2016	0	-10	N/A	-8	N/A
12/31/2015	0	-10	N/A	-7	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-11	N/A	-7	N/A
3/31/2015	0	-12	N/A	-7	N/A
12/31/2014	0	-13	N/A	-8	N/A
9/30/2014	0	-14	N/A	-8	N/A
6/30/2014	0	-14	N/A	-8	N/A
3/31/2014	0	-16	N/A	-8	N/A
12/31/2013	0	-30	N/A	-6	N/A
9/30/2013	0	-28	N/A	-6	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PHIO devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.5% ).

Bénéfices vs marché: PHIO devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: PHIO devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PHIO ( 213.8% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PHIO ( 213.8% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PHIO devrait être élevé dans 3 ans

Phio Pharmaceuticals Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 33% to US$36.00

Forecast to breakeven in 2025

Price target decreased to US$6.00

Price target decreased to US$6.00

Recent updates

Price target decreased by 33% to US$36.00

Forecast to breakeven in 2025

Phio Pharmaceuticals Corp. Announces Robert M. Infarinato as New Chief Financial Officer

Phio Pharmaceuticals Corp Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research

Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer

Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894

Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding

Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals appoints interim executive chairman

Phio Pharmaceuticals Corp. Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

Phio Pharmaceuticals Discloses Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Phio Pharmaceuticals GAAP EPS of -$0.19 beats by $0.12

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Presents New Data Demonstrating PH-894 Enhances Activity of Her2-Car T Cells At ASGCT 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Price target decreased to US$6.00

Is Phio Pharmaceuticals (NASDAQ:PHIO) In A Good Position To Deliver On Growth Plans?

Phio Pharmaceuticals Corp. Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at AACR Annual Meeting 2022

Phio Pharmaceuticals Corp. Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Price target decreased to US$6.00

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

Phio Pharmaceuticals and AgonOx Inc. Announces Collaboration on Clinical Development of Novel T Cell-Based Cancer Immunotherapies

Phio Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $7.684001 million.

Phio Pharmaceuticals Corp. announced that it has received $14.001908 million in funding

Phio Pharmaceuticals Corp. announced that it expects to receive $14.002049 million in funding

Phio Pharmaceuticals Corp. Announces Positive in Vivo Data on Combination PD-1 and TIGIT Checkpoint Blockade with INTASYL in a Single Therapeutic for Cancer Treatment

Phio soars 22% on positive in vivo data on combination PD-1 and TIGIT therapy in cancer

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance